# US 7,608,701 B2 · Corticotropin releasing factor 2 receptor agonists > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,608,701 B2 - Document ID: US7608701B2 - Status: Granted - Kind: B2 - Application number: 11/701,576 - Filed: 2007-02-02 - Published: 2009-05-14 - Granted: 2009-10-27 - Earliest claimed: 2002-01-16 - Assignees: The Procter & Gamble Company - Inventors: Robert Joseph Isfort; Wieslaw Adam Mazur - Web page: https://patentgrep.com/patent/US7608701B2 ## CPC - C07K 14/57509: {Corticotropin releasing factor [CRF] (Urotensin)} - A61P 5/38: of the suprarenal hormones - A61P 21/00: Drugs for disorders of the muscular or neuromuscular system - A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps - A61P 21/04: for myasthenia gravis - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy. ## Claims ### Claim 1 An isolated nucleic acid encoding a non-native peptide, wherein the non-native peptide comprises the sequence ZGPPISIDLPX11X12LLRKX17IEIEKQEKEKQQAX31X32NAX35X36LX38X39X40 (SEQ ID NO: 531); wherein: X11 is selected from F, Y, L, I, and T; X12 is selected from Q, W, and Y; X17 is selected from V and M; X31 is selected from T and A; X32 is selected from N and T; X35 is selected from R and L; X36 is selected from L and I; X38 is selected from D and A; X39 is selected from T and R; and X40 is selected from I and V; and variants thereof having at least 95% sequence identity to said peptide. ### Claim 2 (depends on 1) An isolated nucleic acid according to claim 1, wherein the variant has at least 97% sequence identity to said non-native peptide. ### Claim 3 An isolated nucleic acid encoding for a non-native peptide, wherein the non-native peptide comprises the sequence of SEQ ID NO: 278, and variants thereof having at least 95% sequence identity to said non-native peptide. ### Claim 4 (depends on 3) An isolated nucleic acid according to claim 3, wherein the variant has at least 97% sequence identity to said non-native peptide. ### Claim 5 (depends on 1) An isolated nucleic acid according to claim 1, wherein X11 is selected from F, L, T, and Y. ### Claim 6 (depends on 1) An isolated nucleic acid according to claim 1, wherein X11X12 are selected from the group consisting of FQ, YQ, YW, LQ, LY, IY, and TY. ### Claim 7 (depends on 6) An isolated nucleic acid according to claim 6, wherein X31X32 are selected from the group consisting of AN, and TT. ### Claim 8 (depends on 7) An isolated nucleic acid according to claim 7, wherein X35X36 are selected from the group consisting of RL, LL, and RI. ### Claim 9 (depends on 7) An isolated nucleic acid according to claim 7, wherein X38X39X40 are selected from the group consisting of DTI, ARI, ATI, DRV, and ARV. ### Claim 10 (depends on 6) An isolated nucleic acid according to claim 6, wherein X35X36 are selected from the group consisting of RL, LL, and RI. ### Claim 11 (depends on 6) An isolated nucleic acid according to claim 6, wherein X38X39X40 are selected from the group consisting of DTI, ARI, ATI, DRV, and ARV. ### Claim 12 (depends on 1) An isolated nucleic acid according to claim 1, wherein X31X32 are selected from the group consisting of AN, and TT. ### Claim 13 (depends on 12) An isolated nucleic acid according to claim 12, wherein X35X36 are selected from the group consisting of RL, LL, and RI. ### Claim 14 (depends on 13) An isolated nucleic acid according to claim 13 wherein X38X39X40 are selected from the group consisting of DTI, ARI, ATI, DRV, and ARV. ### Claim 15 (depends on 12) An isolated nucleic acid according to claim 12, wherein X38X39X40 are selected from the group consisting of DTI, ARI, ATI, DRV, and ARV. ### Claim 16 (depends on 1) An isolated nucleic acid according to claim 1, wherein X35X36 are selected from the group consisting of RL, LL, and RI. ### Claim 17 (depends on 16) An isolated nucleic acid according to claim 16, wherein X38X39X40 are selected from the group consisting of DTI, ARI, ATI, DRV, and ARV. ### Claim 18 (depends on 1) An isolated nucleic acid according to claim 1, wherein X38X39X40 are selected from the group consisting of DTI, ARI, ATI, DRV, and ARV. ### Claim 19 (depends on 1) An isolated nucleic acid according to claim 1, wherein the non-native peptide comprises a sequence selected from the group consisting of SEQ ID NO: 22, 144, 148, 149, 151, 278, 279, 286, 288, 311, 349, 350, 351, 352, and 353. ### Claim 20 An isolated nucleic acid encoding for a non-native peptide, wherein the non-native peptide comprises the sequence ZGPPISIDLPX11X12LLRKX17IEIEKQEKEKQQAX31X32NAX35X36LX38X39X40 (SEQ ID NO: 531); wherein: X11 is selected from F, Y, L, I, and T; X12 is selected from Q, W, and Y; X17 is selected from V and M; X31 is selected from T and A; X32 is selected from N and T; X35 is selected from R and L; X36 is selected from L and I; X38 is selected from D and A; X39 is selected from T and R; and X40 is selected from I and V. ### Claim 21 An isolated nucleic acid encoding for a non-native peptide, wherein the non-native peptide comprises the sequence of SEQ ID NO: 278.